Acquisitions not a cure for anti-infectives.
Bradley
David
D
D000077612:Anidulafungin; D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D015780:Carbapenems / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D000077726:Doripenem; D004345:Drug Industry / Q000191:economics / Q000639:trends; D054714:Echinocandins; D017850:Economics, Pharmaceutical / Q000639:trends*; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D010456:Peptides, Cyclic / Q000627:therapeutic use; D017334:Teicoplanin / Q000031:analogs & derivatives
D000890:Anti-Infective Agents; D015780:Carbapenems; D054714:Echinocandins; D006020:Glycopeptides; D010456:Peptides, Cyclic; D017334:Teicoplanin; C469289:dalbavancin; D000077612:Anidulafungin; D000077726:Doripenem